Caroline Van Holsbeke

Polytomous diagnosis of ovarian tumors as benign, borderline, primary invasive or metastatic: development and validation of standard and kernel-based risk prediction models

Sabine Van Huffel, Dirk Timmerman, Tom Bourne, 2010, BMC medical research methodology.

Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group

Sabine Van Huffel, Dirk Timmerman, Ignace Vergote, 2010, BMJ : British Medical Journal.

Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study

Dirk Timmerman, Tom Bourne, Stefano Guerriero, 2014, BMJ : British Medical Journal.

External Validation of Mathematical Models to Distinguish Between Benign and Malignant Adnexal Tumors: A Multicenter Study by the International Ovarian Tumor Analysis Group

Sabine Van Huffel, Dirk Timmerman, Enrico Ferrazzi, 2007, Clinical Cancer Research.

Clinical Utility of Risk Models to Refer Patients with Adnexal Masses to Specialized Oncology Care: Multicenter External Validation Using Decision Curve Analysis

Dirk Timmerman, Jan Y Verbakel, Tom Bourne, 2017, Clinical Cancer Research.

Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors.

Sabine Van Huffel, Dirk Timmerman, Ignace Vergote, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defining safe criteria to diagnose miscarriage: prospective observational multicentre study

Dirk Timmerman, Tom Bourne, Ben Van Calster, 2015, BMJ : British Medical Journal.

Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.

Patrick Neven, Sabine Van Huffel, Dirk Timmerman, 2007, Journal of the National Cancer Institute.